555 results on '"Forconi, Francesco"'
Search Results
2. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment
3. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
4. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
5. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL
6. IL-4 enhances expression and function of surface IgM in CLL cells
7. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation
8. Perturbation of the normal immune system in patients with CLL
9. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
10. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features
11. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
12. Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
13. DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1
14. EMT-like Activation in CLL Provides Novel Therapeutic Target
15. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK
16. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
17. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function
18. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis
19. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
20. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
21. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
22. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma
23. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
24. Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E
25. Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
26. Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance
27. Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial
28. Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior
29. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia
30. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia
31. The normal IGHV1-69–derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL
32. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior
33. Exploring the pathways to chronic lymphocytic leukemia
34. Time for a new prognostic score in CLL?
35. Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial
36. Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia
37. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
38. IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution
39. Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL
40. Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia
41. Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets
42. High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients
43. Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia
44. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch
45. Hedgehog activation in CLL
46. Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
47. NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia
48. Immunoglobulin Variable Region Gene Sequences Reveal N-Glycosylation Motifs As an Early and Stable Event in Follicular Lymphoma Pathology
49. Lymphoma-Specific Subversion of B-Cell Receptor Signaling By Macrophage Lectins
50. Acquisition of Mannoses on the Surface Immunoglobulin Binding Site Reveals Functional Status and Cell of Origin in Diffuse Large B Cell Lymphomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.